A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

@article{Roy2004ARC,
  title={A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.},
  author={Denis Roy and Brian H. Rowe and Ian G Stiell and Benoit Coutu and John H. Ip and Denis Phaneuf and Jacques Lee and Humberto J. Vidaillet and Garth Dickinson and Sheila Grant and Alan M. Ezrin and Gregory N. Beatch},
  journal={Journal of the American College of Cardiology},
  year={2004},
  volume={44 12},
  pages={2355-61}
}
OBJECTIVES The purpose of this study was to determine the efficacy and safety of intravenous RSD1235 in terminating recent onset atrial fibrillation (AF). BACKGROUND Anti-arrhythmic drugs currently available to terminate AF have limited efficacy and safety. RSD1235 is a novel atrial selective anti-arrhythmic drug. METHODS This was a phase II, multi-centered, randomized, double-blinded, step-dose, placebo-controlled, parallel group study. Fifty-six patients from 15 U.S. and Canadian sites… CONTINUE READING